COMPLICATIONS OF GASTROESOPHAGEAL REFLUX DISEASE IN ELDERLY PATIENTS

Download full text PDF
Issue: 
6
Year: 
2015

Professor E. Onuchina (1), MD; S. Brikova (2); Yu. Belikova (2); S. Gontarenko (2) 1 -Irkutsk State Medical Academy of Postgraduate Education 2 -War Veterans Hospital, Irkutsk

The incidence of complicated gastroesophageal reflux disease is more than 2.5-fold higher in elderly people. The age factor is of the greatest importance for mucosal ulceration in the distal esophagus. The proton pump inhibitor (PPI)alginate (Gaviscon®) combination is a more pathogenetically sound treatment than PPI monotherapy.

Keywords: 
gastroesophageal reflux disease
elderly age
sodium alginate
Gaviscon®
Gaviscon-double action®



It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Onuchina E.V., Brikova S.I., Tsukanov V.V. Ispol'zovanie preparata Geviskon dlja kupirovanija simptomatiki pischevodnyh, vnepischevodnyh sindromov i funktsional'noj dispepsii u bol'nyh GERB pozhilogo i starcheskogo vozrasta // Eksperim. i klin. gastroenterol. – 2010; 10: 80–6.
  2. Onuchina E.V. Klinicheskie projavlenija, faktory riska i effektiv nost' lechenija gastroezofageal'noj refljuksnoj bolezni u lits pozhilogo vozrasta. Avtoref. dis. …d-ra med. nauk. Krasnojarsk, 2011; s. 45.
  3. Ang, D., Sifrim D., Tack J. Mechanisms of heartburn // Nat. Clin. Pract. Gastroenterol. Hepatol. – 2008; 5: 383–92.
  4. Corley D., Kubo A., Levin T. et al. Race, ethnicity, sex and temporal differences in Barrett's oesophagus diagnosis: a large community-based study, 1994–2006 // Gut. – 2009; 58: 182–8.
  5. Farr5. é R., Fornari F., Blondeau K. et al. Acid and weakly acidic solutions impair mucosal integrity of distal exposed and proximal non-exposed human oesophagus // Gut. – 2010; 59: 164–9.
  6. Kwiatek M., Roman S., Fareeduddin A. et al. An alginate-antacid formulation 6. (Gaviscon Double Action Liquid) can eliminate or displace the postprandial 'acid pocket' in symptomatic GERD patients // Aliment. Pharmacol. Ther. – 2011; 34: 59–66.
  7. Lien H., Chang C., Yeh H. et al. Increasing prevalence of erosive esophagitis 7. among Taiwanese aged 40 years and above: a comparison between two time periods // J. Clin. Gastroenterol. – 2009; 43: 926–32.
  8. Lundell L., Dent J., Bennet J. Endoscopic assessment of oesophagitis 8. clinical and fuctional correlates and futher validation of Los Angeles classification // Gut. – 1999; 45: 72–180.
  9. Murray L., Watson P., Johnston B. et al. Risk of adenocarcinoma in Barrett's 9. oesophagus: population based study // BMJ. – 2003; 327: 534–5.
  10. Salvioli G., Tambara E., Gaetti E. et al. Chemico-physical property and bile 10. acid binding capacity of several antacids // Minerva Dietol/Gastroenterol. – 1989; 35: 79–83.
  11. Savarino E., de Bortoli N., Zentilin P. et al. Alginate controls hearburn in 11. patients with erosive and nonerosive reflux disease // World J. Gastroenterol. – 2012; 18: 4371–8.
  12. Spechler S., Sharma P., Souza R. et al. American Gastroenterological 12. Association technical review on the management of Barrett's esophagus // Gastroenterology. – 2011; 140: 18–52.
  13. Strugala V., Avis J., Jolliffe I.G. et al. The role of an alginate suspension on 13. pepsin and bile acids – key aggressors in the gastric refluxate. Does this have implications for the treatment of gastro-oesophageal reflux disease? // J. Pharm. Pharmacol. – 2009; 61: 1021–8.
  14. Vakil N., van Zanten S., Kahrilas P. et al. The Monreal Definition and 14. Classification of gastroesophageal reflux disease: a global evidence-based consensus // Am. J. Gastroenterology. – 2006; 101: 1900–20.
  15. Zerbib F., Roman S., Ropert A., et al. Esophageal pH-impedance monitoring 15. and symptom analysis in GERD: a study in patients off and on therapy // Am. J. Gastroenterol. – 2006; 101: 1956–63.
  16. Hampson F. et al. Alginate rafts and their characterization // Int. J. Pharm. – 16. 2005; 294 (1–2): 137–47.COMPLICATIONS OF GAST